E2853. Use of Radioembolization and Immune Checkpoint Inhibitors in the Management of Hepatocellular Carcinoma: Current Standard of Therapy
Authors
Suryansh Bajaj;
University of Arkansas for Medical Sciences
Divya Nayar;
University of Arkansas for Medical Sciences
Background
Primary liver cancer is the seventh leading cancer in humans and is the third most common cause of cancer mortality worldwide. Hepatocellular carcinoma (HCC) constitutes 75% - 80% of these primary liver cancers and is the second most common cause of cancer-related mortality in men and the sixth most common cause of cancer-related mortality in women. Combination of transarterial radioembolization (TARE) and immune checkpoint inhibitors (ICI) is one of the best management strategies. The purpose of this exhibit is to review the mechanisms, safety profile, current clinical data, and limitations.
Educational Goals / Teaching Points
Epidemiology and pathogenesis of HCC, overview of radiotherapy and immunotherapy, synergistic mechanism of radiotherapy and immunotherapy, current clinical applications, current clinical data, safety profile, ongoing clinical trials for the use of combination of Y-90 radioembolization and ICIs in advance HCC, limitations, and future directions.
Key Anatomic/Physiologic Issues and Imaging Findings/Techniques
Hepatocellular carcinoma, transarterial radioembolization (TARE) and immune checkpoint inhibitors (ICI).
Conclusion
Radioembolization and immunotherapy are effective treatments that offer promise to patients with historically challenging disease. Both therapies have separate mechanisms of action and may potentially be synergistic. A combination approach could hold promise and warrants continued investigation.
